Ratings Carl Zeiss Meditec AG Börse Stuttgart

Equities

AFX

DE0005313704

Market Closed - Börse Stuttgart Other stock markets 15:51:55 2024-06-19 EDT			5-day change	1st Jan Change
65.5 ^EUR	-1.06%		-23.82%	-32.64%

06-19	CARL ZEISS MEDITEC : CZM’s eye attractiveness fades
06-18	CARL ZEISS MEDITEC : CZM’s eye attractiveness fades

Strengths

The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company benefits from high valuations in earnings multiples.
The company is highly valued given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
Over the past twelve months, analysts' opinions have been revised negatively.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
CARL ZEISS MEDITEC AG	-32.64%	6.38B	-
THERMO FISHER SCIENTIFIC	+7.23%	217B	B
DANAHER CORPORATION	+11.31%	191B	B-
INTUITIVE SURGICAL, INC.	+28.94%	154B	B-
BOSTON SCIENTIFIC CORPORATION	+32.00%	112B	A-
SIEMENS HEALTHINEERS AG	-0.46%	62.84B	A-
EDWARDS LIFESCIENCES CORPORATION	+16.09%	53.34B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+0.94%	48.83B	B+
AGILENT TECHNOLOGIES, INC.	-2.97%	39.36B	A
GE HEALTHCARE TECHNOLOGIES INC.	+1.23%	35.73B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes